Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Segundo Mariz

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Frontiers in Medicine|September 13, 2021
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's PerspectiveMaria E Sheean, Frauke Naumann-Winter, Giuseppe Capovilla, et al.
The Oncologist|May 4, 2023
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase InhibitorsC Mircea S Tesileanu, Sotirios Michaleas, Rocio Gonzalo Ruiz, et al.
Drug Discovery Today|October 9, 2017
Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditionsMaria E Sheean, Violeta Stoyanova-Beninska, Giuseppe Capovilla, et al.
Nature Reviews. Drug Discovery|April 4, 2019
Defining orphan conditions in the context of the European orphan regulation: challenges and evolutionDaniel J O'Connor, Maria E Sheean, Matthias P Hofer, et al.
Drug Discovery Today|November 10, 2019
Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseasesMaria E Sheean, Eva Malikova, Dinah Duarte, et al.
Nature Reviews. Drug Discovery|May 3, 2011
European regulation on orphan medicinal products: 10 years of experience and future perspectives, Kerstin Westermark, Birthe Byskov Holm, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Frontiers in Medicine|September 13, 2021
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's PerspectiveMaria E Sheean, Frauke Naumann-Winter, Giuseppe Capovilla, et al.
The Oncologist|May 4, 2023
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase InhibitorsC Mircea S Tesileanu, Sotirios Michaleas, Rocio Gonzalo Ruiz, et al.
Drug Discovery Today|October 9, 2017
Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditionsMaria E Sheean, Violeta Stoyanova-Beninska, Giuseppe Capovilla, et al.
Nature Reviews. Drug Discovery|April 4, 2019
Defining orphan conditions in the context of the European orphan regulation: challenges and evolutionDaniel J O'Connor, Maria E Sheean, Matthias P Hofer, et al.
Drug Discovery Today|November 10, 2019
Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseasesMaria E Sheean, Eva Malikova, Dinah Duarte, et al.
Nature Reviews. Drug Discovery|May 3, 2011
European regulation on orphan medicinal products: 10 years of experience and future perspectives, Kerstin Westermark, Birthe Byskov Holm, et al.
Pageof 3